What are the current drug manufacturers of melphalan/melphalan for injection?

Melphalan for injection/Melphalan flufenamide is an innovative drug developed by Oncopeptides. It is mainly used to treat multiple myeloma (MM) and amyloid light chain amyloidosis. The drug is unique in its chemical structure, which is the ethyl ester of a lipophilic dipeptide consisting of melphalan and p-fluoro-L-phenylalanine. Due to its lipophilicity, melphalan-flufenamide can quickly penetrate the cell membrane and be hydrolyzed by aminopeptidase in the cytoplasm to generate more hydrophilic alkylated molecules, such as melphalan and desethyl-melflufen, thereby exerting anti-tumor effects.

Currently, the main manufacturer of melphalan for injection isOncopeptides. The company focuses on developing innovative anti-tumor drugs, particularly in hematological malignancies.

Oncopeptides received marketing approval for this drug in combination with dexamethasone in February 2021 for adult patients with relapsed or refractory (R/R) multiple myeloma. The drug's approval marks a new addition to the treatment options in this area, especially for patients who have not responded well to multiple treatments.

In addition toOncopeptides, some other pharmaceutical companies on the market have begun to pay attention to the research and development and production of melphalan drugs, but the specific manufacturer information may be limited. Because the drug has specific indications and a complex production process, it usually requires a pharmaceutical company with the appropriate technology and facilities to produce it.

As the global demand for anti-tumor drugs continues to grow, the market prospects for injectable melphalan are broad. Many pharmaceutical companies are increasing investment in the research and development of new oncology drugs. Through the continuous advancement of clinical trials, these companies not only hope to expand the indications of existing drugs, but also hope to find more effective treatments in different tumor types.